We are live on ! Find out more
PTGX icon

Protagonist Therapeutics
PTGX

38 hedge funds and large institutions have $175M invested in Protagonist Therapeutics in 2016 Q4 according to their latest regulatory filings, with 8 funds opening new positions, 21 increasing their positions, 6 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

250% more repeat investments, than reductions

Existing positions increased: 21 | Existing positions reduced: 6

100% more funds holding in top 10

Funds holding in top 10: 1 → 2 (+1)

100% more first-time investments, than exits

New positions opened: 8 | Existing positions closed: 4

47.74% more ownership

Funds ownership: 0% → 47.74% (+48%)

21% more capital invested

Capital invested by funds: $145M → $175M (+$30.2M)

12% more funds holding

Funds holding: 34 → 38 (+4)

Holders
38
Holders Change
+4
Holders Change %
+11.76%
% of All Funds
0.95%
Holding in Top 10
2
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+100%
% of All Funds
0.05%
New
8
Increased
21
Reduced
6
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

1
Fidelity Investments
Fidelity Investments
Massachusetts
+$8.44M
2
Vanguard Group
Vanguard Group
Pennsylvania
+$3.74M
3
Northern Trust
Northern Trust
Illinois
+$1.38M
4
BFA
BlackRock Fund Advisors
California
+$846K
5
State Street
State Street
Massachusetts
+$692K

Top Sellers

1
BI
BVF Inc
California
-$7.92M
2
CAM
Cormorant Asset Management
Massachusetts
-$1.78M
3
DCM
DAFNA Capital Management
California
-$1.74M
4
RCM
RA Capital Management
Massachusetts
-$1.38M
5
Adage Capital Partners
Adage Capital Partners
Massachusetts
-$1.11M
Name Holding Trade Value Shares
Change 		Change in
Stake
Wells Fargo
26
Wells Fargo
California
$115K +$116K +5,219 New
NFA
27
Nationwide Fund Advisors
Ohio
$108K +$63.2K +2,833 +135%
Deutsche Bank
28
Deutsche Bank
Germany
$94K +$68.5K +3,073 +242%
BA
29
BlackRock Advisors
Delaware
$61K +$3.41K +153 +6%
SO
30
STRS Ohio
Ohio
$52K – – –
UBS Group
31
UBS Group
Switzerland
$32K +$8.34K +374 +35%
Legal & General Group
32
Legal & General Group
United Kingdom
$30K +$29.9K +1,343 New
Bank of America
33
Bank of America
North Carolina
$23K +$23.3K +1,043 New
Creative Planning
34
Creative Planning
Kansas
$15K +$11.1K +500 +282%
Royal Bank of Canada
35
Royal Bank of Canada
Ontario, Canada
$8K +$3.5K +157 +79%
BNP Paribas Financial Markets
36
BNP Paribas Financial Markets
France
$7.98K +$2.05K +92 +34%
BlackRock
37
BlackRock
New York
$6K +$5.84K +262 New
Barclays
38
Barclays
United Kingdom
$5K +$4.86K +218 New
BI
39
BVF Inc
California
– -$7.92M -375,000 Closed
CS
40
Credit Suisse
Switzerland
– -$358K -16,924 Closed
Goldman Sachs
41
Goldman Sachs
New York
– -$282K -13,340 Closed
Jane Street
42
Jane Street
New York
– -$232K -10,964 Closed
1
2

PTGX Hedge Fund Activity: Q4 2016 in Review

38 of the 4,000 institutional investors tracked by Wall St. Rank reported a position in Protagonist Therapeutics (PTGX) for Q4 2016, worth a combined $175M — up 21% from $145M a quarter earlier.

Buyers outnumbered sellers: 8 funds opened new PTGX positions and 4 closed out — a net gain of 4 holders — while 21 added to existing stakes and 6 trimmed.

The largest buyer was Fidelity Investments, adding an estimated $8.44M. The largest seller was BVF Inc, exiting entirely with an estimated $7.92M sold.

  • 38 institutional investors held Protagonist Therapeutics (PTGX) as of Q4 2016, up from 34 in Q3 2016.
  • Funds reported $175M of Protagonist Therapeutics stock for Q4 2016, up 21% quarter-over-quarter.
  • 8 funds opened new Protagonist Therapeutics positions in Q4 2016 and 4 closed out, a net change of +4 holders.
  • The largest Protagonist Therapeutics buyer in Q4 2016 was Fidelity Investments, an estimated $8.44M added.
  • The largest Protagonist Therapeutics seller in Q4 2016 was BVF Inc, an estimated $7.92M sold.

Based on aggregated 13F filings for Q4 2016.